Algeta ASA is increasing manufacturing capacity for its lead product, a radiopharmaceutical, as recruitment continues in a pivotal Phase 3 trial of the product in patients with bone metastases arising from hormone-refractory prostate cancer. ---Subscribe to MedNous to access this article--- Company News
